Autor/es de la URV: | Capilla Luque, Javier / Guarro Artigas, Josep / Sanchis Talón, Marta
|
Autor según el artículo: | Sanchis, Marta; Capilla, Javier; Castanheira, Mariana; Martin-Vicente, Adela; Sutton, Deanna A; Fothergill, Annette W; Wiederhold, Nathan P; Guarro, Josep
|
Direcció de correo del autor: | marta.sanchis@urv.cat javier.capilla@urv.cat
|
Identificador del autor: | 0000-0001-7251-6792 0000-0002-0765-6403
|
Año de publicación de la revista: | 2016
|
Tipo de publicación: | Journal Publications
|
ISSN: | 09248579
|
Referencia de l'ítem segons les normes APA: | Sanchis, Marta; Capilla, Javier; Castanheira, Mariana; Martin-Vicente, Adela; Sutton, Deanna A; Fothergill, Annette W; Wiederhold, Nathan P; Guarro, J (2016). Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. International Journal Of Antimicrobial Agents, 47(4), 286-288. DOI: 10.1016/j.ijantimicag.2015.12.020
|
Referencia al articulo segun fuente origial: | International Journal Of Antimicrobial Agents. 47 (4): 286-288
|
Resumen: | In this study, 27 clinical isolates of Candida glabrata with voriconazole (VRC) minimum inhibitory concentrations (MICs) ranging from ¿0.03 ¿g/mL to 8 ¿g/mL were tested to determine whether in vitro data are predictive of in vivo efficacy. The efficacy of VRC administered at 40 mg/kg was assayed in a neutropenic murine model of disseminated infection by C. glabrata. The reduction in fungal tissue burden in the kidneys was used as a marker of treatment efficacy. VRC reduced the fungal tissue burden in mice infected with strains that had MICs below the epidemiological cut-off value (ECV) of 0.25 ¿g/mL. Variable efficacy of VRC was obtained when the MIC equalled the ECV, and VRC was ineffective when the MIC exceeded the ECV. These results suggest that the use of in vitro data could be useful to predict the outcome for infections by this fungus.
|
DOI del artículo: | 10.1016/j.ijantimicag.2015.12.020
|
Enlace a la fuente original: | https://www.sciencedirect.com/science/article/abs/pii/S0924857916000431?via%3Dihub
|
Versión del articulo depositado: | info:eu-repo/semantics/acceptedVersion
|
Acceso a la licencia de uso: | https://creativecommons.org/licenses/by/3.0/es/
|
Departamento: | Ciències Mèdiques Bàsiques
|
URL Documento de licencia: | https://repositori.urv.cat/ca/proteccio-de-dades/
|
Áreas temáticas: | Saúde coletiva Química Pharmacology (medical) Pharmacology & pharmacy Odontología Nutrição Microbiology (medical) Microbiology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Interdisciplinar Infectious diseases General medicine Farmacia Engenharias iii Engenharias ii Enfermagem Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciências agrárias i Biotecnología Biodiversidade
|
Palabras clave: | Voriconazole Treatment outcome Resistance Model Microbial sensitivity tests Mice Mechanisms Management Male Liposomal amphotericin-b Kidney Fungal infection Fluconazole Fks mutations Epidemiological cut-off value Efficacy Disease models, animal Combination Colony count, microbial Caspofungin Candidiasis Candida glabrata Antifungals Antifungal agents Animals Animal model fungal infection epidemiological cut-off value candida glabrata antifungals animal model
|
Entidad: | Universitat Rovira i Virgili
|
Fecha de alta del registro: | 2025-01-08
|